Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma
Frontiers in Oncology · 18.06.2026 · 16
DOI: 10.3389/fonc.2026.1780688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.06.2026. Verfasst von Tianhui Niu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Reproductive Sciences, Air Force Medical University, Air Force Medical Center, People's Liberation Army, Bei…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric-type endocervical adenocarcinoma (G-EAC) is a rare, highly aggressive malignancy that is not associated with human papillomavirus (HPV) infection. Its occurrence in patients with Peutz-Jeghers syndrome (PJS) is exceptionally rare but clinically critical. In this preliminary study, we performed comprehensive genomic profiling (CGP) using a targeted next-generation sequencing (NGS) panel and immunohistochemistry (IHC) for key biomarkers on a single, well-characterized patient with stage IB3 PJS-associated G-EAC. The primary objective was to identify actionable genomic alterations and potential therapeutic targets to inform personalized treatment strategies. CGP revealed a pathogenic germline STK11 p.K84* mutation, alongside somatic KRAS p.G12A and ERBB3 p.R667S mutations. IHC demonstrated strong, diffuse positivity for Claudin18.2 and MUC6, confirming a gastric phenotype, while p16 was negative. The integration of genomic and proteomic data revealed a primary actionable target, Claudin18.2 (a proven target in gastric cancer), alongside potential actionable alterations involving ERBB signaling. This proof-of-concept study may suggest that integrating CGP and IHC in the management of PJS-associated G-EAC is feasible and could potentially inform clinical decision-making. The identification of these targets could suggest a rationale for incorporating molecular profiling into the standard diagnostic workflow for this aggressive malignancy, potentially improving outcomes through precision oncology approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology and Reproductive Sciences, Air Force Medical University, Air Force Medical Center, People's Liberation Army, Beijing, China.
- Department of Ultrasound, Air Force Medical University, Air Force Medical Center, People's Liberation Army, Beijing, China.
- Laboratory of clinical medicine, Air Force Medical University, Air Force Medical Center, People's Liberation Army, Beijing, China.
Zitieren
APA
Niu, T., Liu, X., Zhang, S., Yu, M., Wang, X., & Jia, J. (2026). Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1780688
Vancouver
Niu T, Liu X, Zhang S, Yu M, Wang X, Jia J. Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1780688
BibTeX
@article{Niu2026,
author = {Niu, Tianhui and Liu, Xiaofang and Zhang, Siqi and Yu, Mengnan and Wang, Xiaoying and Jia, Jinghui},
title = {Mutation profile and therapeutic implications in Peutz-Jeghers syndrome-associated gastric-type endocervical adenocarcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1780688}
}
EUVIMED